News on research grants, RFPs, government funding trends in genetics, genomics, and molecular diagnostics.
The rapid, point-of-care test will be designed to help healthcare providers distinguish between influenza and SARS-CoV-2 in a single sample.
The test is designed to detect and visualize abnormal phosphorylated alpha-synuclein — a hallmark of synucleinopathies — in cutaneous nerve fibers.
Novacyt said that the acquisition secures important intellectual property for its q16 and q32 rapid-PCR instruments for near-patient testing of COVID-19.
Other grant recipients include scientists from the University of Chicago, UCLA, UC Santa Barbara, and the University of Washington.
The test, which is licensed to rHealth, monitors FVIII levels in the blood of patients with hemophilia A patients, who lack the clotting protein.
